Roundtable Discussion: Alpha vs Beta – Is There Ever a Universal Winner?

Key Questions to Be Addressed:

• What biological, clinical and operational factors should ultimately determine whether an alpha- or beta-emitting isotope is the optimal therapeutic choice?
• In which tumour types and disease settings are alpha emitters most likely to deliver a meaningful clinical advantage, and where do beta emitters remain the better option?
• How should developers balance efficacy, safety, manufacturing complexity and isotope availability when selecting an isotope for clinical development?